They are presenting the results of their phase 1/2 trial at a major conference in September. They have already said that ‘multiple’ subjects (that’s at least 2 out of 16 subjects who were giving the drug) showed improvements in hearing thresholds and word recognition scores. Presumably they are going to say how many and by how much at the conference. I’ll definitely be staying tuned for that one.
On a related note, there’s an anecdotal report that one of the participants in the Regain clinical trial in London has bent their confidentiality agreement a little and reported significant improvements in hearing and lowering of tinnitus.
It would be very nice if we had two drugs to treat hearing loss hitting the market (probably years away) at the same time. That would curb price gouging a little.